PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LA JOLLA, Calif. , April 15, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it completed dosing in the first cohort
View HTML
Toggle Summary Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
LA JOLLA, Calif. , April 7, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
Completed Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD") Closed $19M Private Financing LA JOLLA, Calif. , March 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.
View HTML
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
LA JOLLA, Calif. , March 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LA JOLLA, Calif. , Feb. 10, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of the first cohort
View HTML
Toggle Summary Regulus Announces Addition to Board of Directors
LA JOLLA, Calif. , Jan. 27, 2021 /PRNewswire/ --   Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang , Ph.D. has been appointed to the Company's board of
View HTML
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
LA JOLLA, Calif. , Jan. 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity
LA JOLLA, Calif. , Dec. 8, 2020 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced private placement of equity.
View HTML
Toggle Summary Regulus Therapeutics Announces Private Placement of Equity
Definitive Agreement for $19.4 Million in Gross Proceeds LA JOLLA, Calif. , Dec. 1, 2020 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today
View HTML
Toggle Summary Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates
First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")   Restructuring of Sanofi and Oxford Agreements   Receipt of $5 Million Milestone and Material Payments from Sanofi and Proceeds Used to Repay Debt
View HTML